Trial Profile
A Phase II, Open-Label, Randomized, Multi-Centre Study, of Neoadjuvant Olaparib in Patients With Platinum Sensitive Recurrent High Grade Serous Ovarian/Primary Peritoneal or Fallopian Tube Cancer
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 19 Jan 2024
Price :
$35
*
At a glance
- Drugs Olaparib (Primary) ; Carboplatin; Cisplatin
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Biomarker; Pharmacodynamics
- Acronyms NEO
- 14 Jan 2024 Planned End Date changed from 1 Dec 2024 to 31 Dec 2025.
- 14 Jan 2024 Planned primary completion date changed from 1 Dec 2022 to 31 Dec 2025.
- 09 May 2022 Planned End Date changed from 1 Dec 2021 to 1 Dec 2024.